Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Autoimmune Disorders

Free Subscription 15.07.2024 2 Ann Neurol 1 BMC Neurol 1 Diabetes 1 Intern Med 1 J Autoimmun 8 J Clin Endocrinol Metab 2 J Nephrol 9 J Neurol 1 J Pediatr 3 J Pediatr Endocrinol Metab 4 N Engl J Med 1 Neurology 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Neurol

1. GRUT V, Bistrom M, Salzer J, Stridh P, et al
   Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control Study.
   Ann Neurol. 2024;96:302-305.
   PubMed         Abstract available
   
   
2. HU Y, Frisell T, Alping P, Song H, et al
   Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis.
   Ann Neurol. 2024 Jul 10. doi: 10.1002/ana.27026.
   PubMed         Abstract available
   
   

   
   BMC Neurol

3. JIANG W, Wang J, Feng Y, Liu Q, et al
   Neuromyelitis Optica spectrum disorder complicated with pure red cell aplasia: a case report.
   BMC Neurol. 2024;24:241.
   PubMed         Abstract available
   
   

   
   Diabetes

4. GRACE SL, Gillespie KM, Williams CL, Lampasona V, et al
   Autoantibodies to truncated GAD(96-585) antigen stratify risk of early insulin requirement in adult-onset diabetes.
   Diabetes. 2024 Jul 8:db230980. doi: 10.2337/db23-0980.
   PubMed         Abstract available
   
   

   
   Intern Med

5. SATO D, Nishiguchi S, Yamamoto D, Ishioka K, et al
   A Contemporaneous Onset of Eosinophilic Granulomatosis with Polyangiitis and Myasthenia Gravis: A Case Report.
   Intern Med. 2024 Jul 11. doi: 10.2169/internalmedicine.2872.
   PubMed         Abstract available
   
   

   
   J Autoimmun

6. BOGERS L, Rip J, Rijvers L, van Langelaar J, et al
   Impact of coding risk variant IFNGR2 on the B cell-intrinsic IFN-gamma signaling pathway in multiple sclerosis.
   J Autoimmun. 2024;148:103279.
   PubMed         Abstract available
   
   

   
   J Clin Endocrinol Metab

7. XIE P, Shen L, Peng R, Wang Y, et al
   Effects of low-dose methotrexate with MMI in patients with Graves' disease: results of a randomized clinical trial.
   J Clin Endocrinol Metab. 2024 Jul 12:dgae472. doi: 10.1210.
   PubMed         Abstract available
   
   
8. JONSDOTTIR B, Clasen JL, Vehik K, Lernmark A, et al
   Early appearance of thyroid autoimmunity in children followed from birth for type 1 diabetes risk.
   J Clin Endocrinol Metab. 2024 Jul 12:dgae478. doi: 10.1210.
   PubMed         Abstract available
   
   
9. SHAH HS, McGill JB, Hirsch IB, Wu C, et al
   Poor glycemic control is associated with more rapid kidney function decline after the onset of diabetic kidney disease.
   J Clin Endocrinol Metab. 2024 Jan 23:dgae044. doi: 10.1210.
   PubMed         Abstract available
   
   
10. SIMS EK, Cuthbertson D, Jacobsen L, Ismail HM, et al
    Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals.
    J Clin Endocrinol Metab. 2024;109:2116-2123.
    PubMed         Abstract available
    
    
11. ZHOU J, Chen W, Jiang WH, Wu Q, et al
    Altered Static and Dynamic Brain Functional Topological Organization in Patients With Dysthyroid Optic Neuropathy.
    J Clin Endocrinol Metab. 2024;109:2071-2082.
    PubMed         Abstract available
    
    
12. HELLEPUTTE S, Stautemas J, Jansseune L, De Backer T, et al
    Glycaemic management around postprandial exercise in people with type 1 diabetes: Challenge accepted.
    J Clin Endocrinol Metab. 2024 Feb 8:dgae079. doi: 10.1210.
    PubMed         Abstract available
    
    
13. LV Y, Lu X, Liu G, Qi L, et al
    Differential diagnosis of post pancreatitis diabetes mellitus based on pancreatic and gut hormone characteristics.
    J Clin Endocrinol Metab. 2024 Feb 12:dgae080. doi: 10.1210.
    PubMed         Abstract available
    
    
14. KONG YW, Yuan CY, Kiburg K, Brown K, et al
    Treatment satisfaction with Omnipod DASH in adults with type 1 diabetes: A non-blinded 1:1 randomized controlled trial.
    J Clin Endocrinol Metab. 2024 Feb 19:dgae088. doi: 10.1210.
    PubMed         Abstract available
    
    

    
    J Nephrol

15. NAGARAJAH S, Saleh QW, Rasmussen M, Tepel M, et al
    Long non-coding RNA MGAT3 in kidney transplant recipients with immunoglobulin A nephropathy.
    J Nephrol. 2024;37:1133-1135.
    PubMed        
    
    
16. CETINKAYA H, Gursu M, Yazici H, Cebeci E, et al
    Could mesangial C3 deposition be an independent prognostic marker in immunoglobulin A nephropathy?
    J Nephrol. 2024;37:923-932.
    PubMed         Abstract available
    
    

    
    J Neurol

17. ZHU F, Wang WF, Ma CH, Liang H, et al
    Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod.
    J Neurol. 2024 Jul 9. doi: 10.1007/s00415-024-12556.
    PubMed         Abstract available
    
    
18. VITI V, Zanetta C, Capra R, Municchi A, et al
    Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue.
    J Neurol. 2024 Jul 11. doi: 10.1007/s00415-024-12553.
    PubMed        
    
    
19. MAKHANI N, Lebrun-Frenay C, Siva A, Shabanova V, et al
    The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex.
    J Neurol. 2024;271:4019-4027.
    PubMed         Abstract available
    
    
20. PESTCHANKER C, Bertado Cortez B, Lana Peixoto MA, Gortari JI, et al
    Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings.
    J Neurol. 2024;271:4292-4299.
    PubMed         Abstract available
    
    
21. HARTUNG HP, Berger T, Bermel RA, Brochet B, et al
    ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
    J Neurol. 2024;271:4348-4360.
    PubMed         Abstract available
    
    
22. WANG R, Sun D, Wang X, Shi Z, et al
    Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder.
    J Neurol. 2024;271:4503-4512.
    PubMed         Abstract available
    
    
23. ZANGHI A, Borriello G, Bonavita S, Fantozzi R, et al
    Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
    J Neurol. 2024;271:4495-4502.
    PubMed         Abstract available
    
    
24. KAPPOS L, Edan G, Freedman MS, Hartung HP, et al
    Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
    J Neurol. 2024;271:4599-4609.
    PubMed         Abstract available
    
    
25. PREZIOSA P, Amato MP, Battistini L, Capobianco M, et al
    Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders.
    J Neurol. 2024;271:3879-3896.
    PubMed         Abstract available
    
    

    
    J Pediatr

26. GERHOLD K, Al-Azazi S, El-Matary W, Katz LY, et al
    Healthcare Utilization and Direct Costs Prior to Subspecialty Care in Children with Chronic Pain Compared with Other Chronic Childhood Diseases: A Cohort Study.
    J Pediatr. 2024 Apr 4:114046. doi: 10.1016/j.jpeds.2024.114046.
    PubMed         Abstract available
    
    

    
    J Pediatr Endocrinol Metab

27. MULLER-GODEFFROY E, Schmid S, Reinauer C, Galler A, et al
    Mental disorders in children and adolescents with type 1 diabetes before and during the COVID-19 pandemic: results from the DPV registry.
    J Pediatr Endocrinol Metab. 2024;37:586-596.
    PubMed         Abstract available
    
    
28. OZDE S, Akture G, Ozel MA, Yavuzyilmaz F, et al
    Evaluation of the systemic-immune inflammation index (SII) and systemic immune-inflammation response index (SIRI) in children with type 1 diabetes mellitus and its relationship with cumulative glycemic exposure.
    J Pediatr Endocrinol Metab. 2024;37:635-643.
    PubMed         Abstract available
    
    
29. WU S, Yan X, Wu W, Hou L, et al
    Early juvenile cataract in newly diagnosed type 1 diabetic patients: a description of two cases.
    J Pediatr Endocrinol Metab. 2024;37:652-656.
    PubMed         Abstract available
    
    

    
    N Engl J Med

30. CHENG A, Holland SM
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency. Reply.
    N Engl J Med. 2024;391:189-190.
    PubMed        
    
    
31. ROSMARIN D, Amara S, Lebwohl M
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:189.
    PubMed        
    
    
32. COHEN JM, Damsky W
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:188-189.
    PubMed        
    
    
33. FEREDJ E, Cobat A, Casanova JL
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:187-188.
    PubMed        
    
    

    
    Neurology

34. MAYCOCK TJ, Rossor T, Vanegas M, Gringras P, et al
    Child Neurology: Common Occurrence of Narcolepsy Type 1 and Myasthenia Gravis.
    Neurology. 2024;103:e209598.
    PubMed         Abstract available
    
    

    
    PLoS One

35. LI Z, Jia B, Guo Z, Zhang K, et al
    Therapeutic potential of salidroside in type I diabetic erectile dysfunction: Attenuation of oxidative stress and apoptosis via the Nrf2/HO-1 pathway.
    PLoS One. 2024;19:e0306926.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.